Mondias CELEXT07 latest test results confirm effective suppression of grey mould on hops
Momentum Public Relations
Press Release: May 16, 2019
Mondias Naturals Inc. (“Mondias” or the “Company”) (TSXV: NHP) is pleased to announce the results from research on the use of its proprietary CELEXT07 bio-defense stimulant plant extract on hops plants, conducted in collaboration with McGill University.
Global hops production is expected to grow by 3.3% to 122,767 metric tons in 2019 (Source: IHGC – Economic Commission Summary Reports, April 26, 2019). Hops production in the United States alone reached a record high of US$618 million in 2017, up 24% from US$498 million in 2016 (Source: U.S. Department of Agriculture). The global hops market is driven by increasing demand for hops in alcoholic beverages, medicinal drugs and cosmetic formulations. Over the next five years, increased demand for various flavours in beer such as pilsner or lager and the rise in popularity for hop-based craft beer are major factors that will significantly fuel the growth of the global hops market (Source: Persistence Market Research).
The objective of the current series of tests was to measure CELEXT07’s efficacy in suppressing and preventing diseases on hops plants. Hops is a genus belonging to the same taxonomic family as cannabis. Mondias’ latest experiments on cannabis and hops served as proof-of-concept of the efficacy of the Company’s botanicals in plant protection and increasing plant survival by eliciting induced resistance.
Summary of the test results:
- Foliar applications of CELEXT07 bio-defense stimulant extract were very effective in suppressing grey mould (caused by Botrytis cinerea) infections on hops, with decreases of 86% in disease severity and 67% in disease incidence.
- A scheduled dose split over three days for the soil drench application of CELEXT07 also proved effective for the prevention/suppression of grey mould on hops, with decreases of 31% in disease severity and up to 50% in disease incidence.
- Foliar and soil drench application of CELEXT07 did not have any phytotoxic effect on hops.
“These latest results continue to confirm that CELEXT07 is very effective in suppressing and preventing a wide range of fungal and bacterial pathogens, and has applications in more than one large market,” said Jean-Philippe Gravel, Chief Executive Officer of Mondias. “As mentioned in our last release, Mondias has secured the production capacity needed to meet demand from potential clients. CELEXT07 is ready to market and we are presently looking at selling our product through various sales channels and markets, including the agriculture, horticulture, cannabis and hops markets.”
With post-harvest losses of one-third of the food produced worldwide for human consumption (Gastavsson et al., 2011) and annual economic losses of $10 billion to $100 billion worldwide due to grey mould and powdery mildew (L. Hua et al., 2018), the market potential for CELEXT07 is considerable.
About Mondias Natural Products Inc.
Mondias specializes in the commercialization and development of evidence-based botanical products for the health care, bio-agriculture and organic markets. The company sells both oral and topical botanical agents to help manage unmet medical needs through its Holizen Laboratories division. Mondias is also developing botanical-based specialty fertilizers for use on household plants, lawns and golf courses and in urban gardens, nurseries and greenhouses, in collaboration with McGill’s Faculty of Agricultural and Environmental Sciences.
For more information, visit: www.mondias.ca
- Published in Business, Life Sciences, Mondias Natural, News Home, Technology
North Bud Farms Arranges Private Placement Financing and Provides Corporate UpdateMomentum Public Relations Press Release: May 15, 2019
Momentum Public Relations
Press Release: May 15, 2019
North Bud Farms Inc. (CSE: NBUD) (OTCQB: NOBDF) (“NORTHBUD” or the “Company”) announces a non-brokered private placement of up to 13,333,333 units, at a price of $0.30 per unit, for gross proceeds of up to $4 million. Each unit will be comprised of one common share of the Company and one common share purchase warrant. Each warrant will entitle the holder to acquire an additional share at a price of $0.40 for a period of 24 months from the date of closing of the offering. Insiders of the Company have demonstrated their commitment to the continued success of the Company by committing to a lead investment of $1 million in the proposed offering. The Company plans to use the net proceeds of the offering to hire additional staff for its Canadian operations, pursue M&A opportunities in the United States, including new state license applications, and for general working capital purposes.
“These funds will be essential to fund ongoing acquisition efforts in the United States and prepare our Canadian production facility for operations,” said Ryan Brown, CEO of North Bud Farms.
The offering is expected to be completed on or before May 31, 2019, subject to the receipt of all necessary regulatory approvals. All securities issued pursuant to the offering will be subject to a four-month hold period in accordance with applicable Canadian securities laws.
As mentioned, certain directors, officers and other insiders have committed to participate in the offering. Accordingly, any such participation would be considered a “related party transaction” under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company is relying on the exemptions from the formal valuation requirements and majority of the minority shareholder approval requirements of MI 61-101 contained in Section 5.5(a) and Section 5.7(1)(a) in respect of any such related party transaction on the basis that the fair market value of the transaction does not exceed more than 25% of the Company’s market capitalization. The Company expects to file a material change report in respect of any related party transaction on SEDAR prior to the closing of the offering, the whole as required by MI 61-101.
Eureka Vapor LLC Update
The Company is pleased to update shareholders on the status of its planned strategic acquisition of multi-state licensed operator, Eureka Vapor (“Eureka”), as the companies continue to work towards completing a definitive agreement. Based on projected timelines for the completion of the audit of Eureka’s financial statements, the companies expect to sign a definitive agreement in the third quarter of the 2019 calendar year.
“We are excited to be joining forces with NORTHBUD to drive strong long-term revenue growth in both Canada and the United States,” said Justin Braune, CEO of Eureka Vapor. “The Eureka team continues to evaluate synergistic acquisitions in multiple U.S. states to expand both the Eureka Vapor and NORTHBUD brands post-closing of our transaction.”
Corporate Update
The Company is in the final stages of preparation for submission of the required evidence package to Health Canada for its cannabis production facility located in Low, Quebec. Consultants have scheduled the evidence package for the end of June and it will be submitted to Health Canada upon its completion.
“We are very excited to be nearing completion of this project,” said Ryan Brown, CEO of North Bud Farms. “We are equally encouraged by recent changes in the application process that will allocate more resources to companies who are operationally ready. The Company will provide an update post submission of the evidence package.”
About North Bud Farms Inc.
North Bud Farms Inc., through its wholly owned subsidiary GrowPros MMP Inc., is pursuing a licence under The Cannabis Act. North Bud Farms Inc. is constructing a state-of-the-art purpose-built cannabis production facility located on 95 acres of Agricultural Land in Low, Quebec. North Bud Farms Inc. will be focused on Pharmaceutical and Food Grade cannabinoid production in preparation for the legalization of edibles and ingestible products scheduled for October 2019.
For more information visit: www.northbud.com
Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Certain statements and information included in this press release that, to the extent they are not historical fact, constitute forward-looking information or statements (collectively, “forward-looking statements”) within the meaning of applicable securities legislation. Forward-looking statements, including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. Forward-looking statements are based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect.
Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risk factors included in the Company’s final long form prospectus dated August 21, 2018, which is available under the Company’s SEDAR profile at www.sedar.com. Accordingly, readers should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statements to reflect information, events, results, circumstances or otherwise after the date hereof or to reflect the occurrence of unanticipated events, except as required by law including securities laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company.
FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
investors@northbud.com
Sirona Biochem Receives Positive Clinical Results of its Skin Lightening Compound TFC-1067 from China
Momentum Public Relations
Press Release: May 15, 2019
Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (“Sirona“) is pleased to announce results of a clinical trial performed in the Peoples Republic of China (China) using Sirona’s novel skin lightening agent TFC-1067. Sirona’s TFC-1067 once again demonstrated significant clinical lightening effect without any reported adverse effects.
A major distributor of cosmetics materials in China arranged clinical testing of TFC-1067 to be done by a select group of its key cosmetic customers. The formulation used in the studies was the same as that used in Sirona’s first clinical trial in the USA by Dr. Zoe Draelos. The clinical trial design protocols and the testing was conducted independently of Sirona by the cosmetic companies. The studies were conducted in Guangzhou, China.
A total of 60 participants were involved in the studies conducted over several sites. All participants applied the formulation with TFC-1067 twice daily to the face. Each study duration was 4 weeks. During the 4 weeks 90% of participant reported a brightening effect with TFC-1067. Sirona is informed by the distributor that a second set of trials with Sirona’s improved, next generation, formulation is underway.
Dr. Géraldine Deliencourt-Godefroy, Chief Scientific Officer of Sirona Biochem stated, “These are excellent clinical results. Based on the outcome from our first clinical trial, we are pleased to see such results for the short 4-week duration of the testing. This positive testing result on Asian skin with the observed lightening effect supports the clinical effect of TFC-1067 over different skin types. A longer trial is required to assess dyschromia which was assessed in Sirona’s US based clinical trial. Sirona will await feedback on the further testing currently ongoing in China with our new formulation.”
“No clinical safety issues were reported with TFC-1067 during the trial. TFC-1067 has shown a lightening effect over a short clinical trial on Asian skin types.” reports Dr. Howard Verrico, CEO of Sirona Biochem. “Although we prefer to conduct trials with a double blinded protocol using a comparative compound and a longer trial duration as we arranged in the USA, it was important to have these cosmetic companies perform their own clinical testing independently and be confident of the results. TFC-1067 continues to deliver excellent clinical results as anticipated by our preclinical assays. A strong commercial interest in TFC-1067 is already reported by the distributor based on current results.”
“Sirona’s team remains dedicated to work towards entering this market with a safe and effective alternative to current options. We are moving forward on building our relationship with the Chinese distributor with more positive news anticipated near term”, Dr. Verrico concluded.
The global skin lightening market is estimated to grow to US$31.2 billion by 20241. Asia makes up the largest and fastest growing segment of the market. A World Health Organization survey reported that nearly 40 per cent of women polled in China said they regularly used whitening products many of which are toxic2.
______________________________
1 https://www.factmr.com/report/309/skin-lightening-products-market
2 http://theglobalfool.com/tag/mercury/
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
- Published in Business, Life Sciences, News Home, Sirona Biochem
Cannara Biotech Commences Trading on the OTCQB Market in the United States
Momentum Public Relations
Press Release: May 15, 2019
Cannara Biotech (“Cannara” or the “Company”) (CSE: LOVE) (FRA: 8CB) (OTCQB: CNBTF), an emerging vertically integrated cannabis company focused on the cultivation and sale of cannabis and cannabis-infused products to the Canadian and international markets, today announced its common shares are listed for trading on the OTCQB® Venture Market under the trading symbol “CNBTF”.
The Company’s common shares continue to be listed on the Canadian Securities Exchange under the trading symbol “LOVE”.
The OTCQB is a U.S. trading platform operated by the OTC, located in New York. The OTC operates financial markets for approximately 10,000 U.S. and global securities.
“Cannabis and hemp-CBD markets are global markets, with customers, vendors and investors domiciled across all major industrial nations,” said Zohar Krivorot, President and CEO of Cannara. ” Having a listing in the U.S. not only provides easier access for U.S. and international investors to our story, it supports our mission of being a North American premium provider of health and wellness products in large and growing product categories.”
About Cannara Biotech
Cannara Biotech (CSE:LOVE) is building one of the largest indoor cannabis cultivation facilities (625,000 square feet) in Canada and the largest in Quebec. Leveraging Quebec’s low electricity costs, Cannara Biotech’s facility will produce high-grade indoor cannabis and cannabis-infused products for the Canadian and international markets.
- Published in Cannara, Medical Marijuana, News Home
Tetra Bio-Pharma names Di Paola as CFO, Lessard retires
Momentum Public Relations
Press Release: May 14, 2019
Bernard Lessard has retired as chief financial officer of Tetra Bio-Pharma Inc. The company has appointed Sabino Di Paola as his replacement effective May 15.
“Bernard recently advised us of his wish to retire after almost two years in his role of Chief Financial Officer. We are grateful for the valuable contribution that Bernard made during his time with us, bringing the Company from a start-up to what it is today. His drive and focus on performance have strengthened Tetra, and the Company is now well positioned to pursue its growth in this dynamic industry. We wish him the best in his retirement, “said Guy Chamberland, Chief Executive Officer and Chief Scientific Officer.
“We are delighted to appoint Sabino Di Paola to the position of Chief Financial Officer. Sabino was one of the founding members of Tetra and he also contributed to its successful listing on the TSX Venture in 2017. He has a deep understanding of the Company and our industry as well as a profound knowledge of capital markets, having advised many public companies over the years. He joins Tetra at a time where the Company enters another phase of its development. His leadership and experience will be essential in executing our strategic plan and taking the Company to its next level of growth. We are looking forward to working together again,” concluded Mr. Chamberland.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada authorized, and FDA reviewed, clinical trials aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
- Published in Medical Marijuana, News Home, Tetra Bio Pharma
Grown Rogue Announces Ticker Symbol GRUSF on OTC Exchange
Momentum Public Relations
Press Release: May 14, 2019
Grown Rogue International Inc. (CSE: GRIN | OTC: GRUSF) (the “Company” or “Grown Rogue“) reports that the Financial Industry Regulatory Authority (FINRA) has accepted Grown Rogue’s request for a ticker symbol change on the Over the Counter Bulletin Board (OTCBB) from “NVSIF” to “GRUSF”. The Company’s symbol on the Canadian Securities Exchange (CSE) remains unchanged as “GRIN” for Grown Rogue International, Inc. There is no action required by current shareholders in connection with this change.
“An increasing number of United States based investors are looking for investment opportunities in the cannabis sector such as Grown Rogue and our symbol name change on the OTC to GRUSF (Grown Rogue United States) provides improved clarity for US investors looking to buy shares of Grown Rogue which are listed on the CSE,” said Obie Strickler CEO and Co-Founder of Grown Rogue. “In addition to the CSE we are now quoted in US dollars on the OTC for US investors under our new symbol “GRUSF”.
Grown Rogue is now operating or managing assets in three States: Oregon, California, and Michigan. The symbol name change follows the Company’s reverse takeover in November, 2018. The Company indicated no immediate plans to establish the stock for trading on additional exchanges, though the Company anticipates that a Frankfurt listing could soon be in the works.
“Most of our investors are US-based, and increasingly more retail US-based investors have been reaching out through our website and social media channels asking about how they can participate in our growth,” said Jacques Habra, Chief Strategy Officer of Grown Rogue.
Mr. Habra continued, “We have a dedicated office to investor relations that is based in Santa Barbara, California. We expect to hold investor conference calls and eventually an investor only conference as we continue to scale the company across the Country.”
Grown Rogue recently announced the intent to acquire Decibel Farms, owners of the Loud Cannabis Brand, and also announced record monthly revenue of just over $1.01 MM for April, 2019.
“Our vision is that our brand and ticker symbol will be synonymous with a responsible cannabis company focused on value creation,” added Mr. Strickler.
About Grown Rogue
Grown Rogue International Inc. (CSE: GRIN | OTC: GRUSF) is a vertically‐integrated, multi‐state cannabis company curating innovative products to provide consumers with the right cannabis experience. Each of Grown Rogue’s products and strains are categorized and marketed based on unique effects and designed for the full range of a consumer’s lifestyle. Grown Rogue is scaling the vertically integrated model into multiple states by incorporating best‐in‐class manufacturing facilities and a proprietary distribution platform based on Microsoft technology. Grown Rogue’s diverse cannabis product suite includes premium flower, patent‐pending nitrogen sealed pre‐ rolls, oil and concentrates, and edibles featuring a partnership with world‐renowned chocolatier, Jeff Shepherd.
- Published in Cannabis, Grown Rogue, Marijuana, News Home
Arctic Star Receives First Results from 2019 Program in Finland
Momentum Public Relations
Press Release: May 14, 2019
Arctic Star Exploration Corp. (TSXV: ADD) (FSE: 82A1)(“Arctic Star” or the “Company”) is pleased to announce that it has received preliminary results from its regional esker sampling program from its 100% owned Timantti Project in Finland. The Timantti Project consists of two exploration permits surrounded by two exploration reservations totaling 193,700 Hectares near the township of Kuusamo. Last year the company located three diamondiferous kimberlite bodies within the exploration permit, named White, Black and Grey Wolf respectively, and three kimberlite dykes. Fusion from 409.3 kg of kimberlite from these new discoveries yielded 1,032 diamonds. Preliminary results from the esker sampling have highlighted at least three separate areas away from the known kimberlites anomalous in diamond indicator minerals, strong evidence suggests there are many more kimberlites to be found. Kimberlite is the volcanic rock which hosts diamonds and predominantly occurs in groupings averaging a minimum of 30 pipes.
Eskers are the sand gravel remnants of sub glacial melt water river systems dating from the end of the ice age. The company used the publicly available Lidar surveys completed by the Finnish government to map and identify the eskers and plan the sampling program. The company subsequently collected 19 samples that were distributed as evenly as possible within the exploration reservations. The main purpose of the esker sampling was to determine the areal extent of the kimberlite field as efficiently as possible.
Encouragingly the esker samples near the known kimberlites “light” up with diamond indicator minerals. A similar anomaly occurs in an esker system 20km to the North East of the Wolf kimberlites, and two other anomalies occurs 20km and 40km SSE of the Wolf kimberlites respectively.
The eskers samples where processed at CF Minerals in Kelowna, BC using heavy liquids and magnetic separation. The results reported here are from observing and probing 50% of the silicate minerals found in the concentrates. The results for the remaining 50% and the oxide minerals are awaited.
The four esker anomalies consist of Pyrope, Garnet, Fosteritic Olivine, Clinopyroxene and Orthopyroxene with chemistry consistent as being derived from the deep lithosphere.
These new areas will be followed up by closer spaced esker sampling, till sampling and will allow the company to focus planned airborne geophysical surveys.
A program of geophysics and testing magnetic anomalies with an excavator has commenced. Results are expected within 3-4 weeks and will be reported as received.
Kimberlites with significant diamonds will be slated for diamond drill testing to determine size, and promising magnetic anomalies that could not be trenched due to till depth will also be drill tested.
Qualified Person
The technical data in this news release has been reviewed and approved by Buddy Doyle, a diamond geologist with over 30 years of experience, a Qualified Person under the provisions of National Instrument 43-101.
About Arctic Star
The Company owns 100% of the recently acquired Timantti Diamond Project including a 243 Ha Exploration Permit and a 193,700 Ha Exploration Reservation near the town of Kuusamo, in Finland. The project is located approximately 550km SW of the operating Grib Diamond Mine in Russia. Arctic has commenced its exploration in Finland on the Timantti Project, where four diamondiferous kimberlite bodies may represent the first finds in a large kimberlite field. The Company also controls diamond exploration properties in Nunavut (Stein), the NWT (Diagras and Redemption).
Arctic Star has a highly experienced diamond exploration team previously responsible for several world class diamond discoveries.
ON BEHALF OF THE BOARD OF DIRECTORS OF
ARCTIC STAR EXPLORATION CORP.
“Patrick Power”
Patrick Power, President & CEO
+1 (604) 218-8772
ppower@arcticstar.ca
- Published in Arctic Star Exploration, Mining, News Home